Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 4/2013

01.08.2013 | ORIGINAL ARTICLE

Beneficial Effects of Intracoronary Nicorandil on Microvascular Dysfunction After Primary Percutaneous Coronary Intervention: Demonstration of Its Superiority to Nitroglycerin in a Cross-Over Study

verfasst von: Noritoshi Ito, Shinsuke Nanto, Yasuji Doi, Yuma Kurozumi, Tomoaki Natsukawa, Hiroyuki Shibata, Masaya Morita, Atsushi Kawata, Ayumu Tsuruoka, Hirotaka Sawano, Ken-ichiro Okada, Yasuhiko Sakata, Tatsuro Kai, Toru Hayashi

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In patients undergoing primary percutaneous coronary intervention (PCI) for the treatment of ST-segment elevation myocardial infarction (STEMI), coronary microvascular dysfunction is associated with poor prognosis. Coronary microvascular resistance is predominantly regulated by ATP-sensitive potassium (KATP) channels. The aim of this study wasto clarify whether nicorandil, a hybrid KATP channel opener and nitric oxide donor, may be a good candidate for improving microvascular dysfunction even when administered after primary PCI.

Methods

We compared the beneficial effects of nicorandil and nitroglycerin on microvascular function in 60 consecutive patients with STEMI. After primary PCI, all patients received single intracoronary administrations of nitroglycerin (250 μg) and nicorandil (2 mg) in a randomized order; 30 received nicorandil first, while the other 30 received nitroglycerin first. Microvascular dysfunction was evaluated with the index of microcirculatory resistance (IMR), defined as the distal coronary pressure multiplied by the hyperemic mean transit time.

Results

As a first administration, nicorandil decreased IMR significantly more than did nitroglycerin (median [interquartile ranges]: 10.8[5.2–20.7] U vs. 2.1[1.0–6.0] U, p = 0.0002).As a second administration, nicorandil further decreased IMR, while nitroglycerin did not (median [interquartile ranges]: 6.0[1.3–12.7] U vs. −1.4[−2.6 to 1.3] U, p < 0.0001). The IMR after the second administration was significantly associated with myocardial blush grade, angiographic TIMI frame count after the procedure, and peak creatine kinase level.

Conclusion

Intracoronary nicorandil reduced microvascular dysfunction after primary PCI more effectively than did nitroglycerin in patients with STEMI, probably via its KATP channel-opening effect.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223–8.PubMedCrossRef Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223–8.PubMedCrossRef
2.
Zurück zum Zitat Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the “dark side” of reperfusion. Circulation. 2009;120:2105–12.PubMedCrossRef Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the “dark side” of reperfusion. Circulation. 2009;120:2105–12.PubMedCrossRef
3.
Zurück zum Zitat Ito N, Nanto S, Doi Y, et al. High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil. Circ J. 2010;74:909–16.PubMedCrossRef Ito N, Nanto S, Doi Y, et al. High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil. Circ J. 2010;74:909–16.PubMedCrossRef
4.
Zurück zum Zitat Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003;107:3129–32.PubMedCrossRef Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003;107:3129–32.PubMedCrossRef
5.
Zurück zum Zitat McGeoch R, Watkins S, Berry C, et al. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2010;3:715–22.PubMedCrossRef McGeoch R, Watkins S, Berry C, et al. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2010;3:715–22.PubMedCrossRef
6.
Zurück zum Zitat Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am CollCardiol. 2008;51:560–5.CrossRef Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am CollCardiol. 2008;51:560–5.CrossRef
7.
Zurück zum Zitat Lim HS, Yoon MH, Tahk SJ, et al. Usefulness of the index of microcirculatory resistance for invasively assessing myocardial viability immediately after primary angioplasty for anterior myocardial infarction. Eur Heart J. 2009;30:2854–60.PubMedCrossRef Lim HS, Yoon MH, Tahk SJ, et al. Usefulness of the index of microcirculatory resistance for invasively assessing myocardial viability immediately after primary angioplasty for anterior myocardial infarction. Eur Heart J. 2009;30:2854–60.PubMedCrossRef
8.
Zurück zum Zitat Kern MJ, Miller JT, Henry RL. Dose-related effects of intracoronary nitroglycerin on coronary hyperemia in patients with coronary artery disease. Am Heart J. 1986;111:845–52.PubMedCrossRef Kern MJ, Miller JT, Henry RL. Dose-related effects of intracoronary nitroglycerin on coronary hyperemia in patients with coronary artery disease. Am Heart J. 1986;111:845–52.PubMedCrossRef
9.
Zurück zum Zitat Kurz MA, Lamping KG, Bates JN, et al. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res. 1991;68:847–55.PubMedCrossRef Kurz MA, Lamping KG, Bates JN, et al. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res. 1991;68:847–55.PubMedCrossRef
10.
Zurück zum Zitat Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J. 1997;133:616–21.PubMedCrossRef Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J. 1997;133:616–21.PubMedCrossRef
11.
Zurück zum Zitat De Bruyne B, Pijls NH, Smith L, Wievegg M, Heyndrickx GR. Coronary thermodilution to assess flow reserve: experimental validation. Circulation. 2001;104:2003–6.PubMedCrossRef De Bruyne B, Pijls NH, Smith L, Wievegg M, Heyndrickx GR. Coronary thermodilution to assess flow reserve: experimental validation. Circulation. 2001;104:2003–6.PubMedCrossRef
12.
Zurück zum Zitat Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–30.PubMedCrossRef Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–30.PubMedCrossRef
13.
Zurück zum Zitat Costantini CO, Stone GW, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting with and without glycoprotein IIb/IIIa inhibition in acute myocardial infarction. J Am CollCardiol. 2004;44:305–12.CrossRef Costantini CO, Stone GW, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting with and without glycoprotein IIb/IIIa inhibition in acute myocardial infarction. J Am CollCardiol. 2004;44:305–12.CrossRef
14.
Zurück zum Zitat Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am CollCardiol. 1985;5:587–92.CrossRef Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am CollCardiol. 1985;5:587–92.CrossRef
15.
Zurück zum Zitat Doddi S, Marathe A, Ravi SS, Torney DC. Discovery of association rules in medical data. Med Inform Internet Med. 2001;26:25–33.PubMedCrossRef Doddi S, Marathe A, Ravi SS, Torney DC. Discovery of association rules in medical data. Med Inform Internet Med. 2001;26:25–33.PubMedCrossRef
16.
Zurück zum Zitat The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010;1:2–20. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010;1:2–20.
17.
Zurück zum Zitat Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284–8.PubMedCrossRef Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284–8.PubMedCrossRef
18.
Zurück zum Zitat Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33:654–60.PubMedCrossRef Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33:654–60.PubMedCrossRef
19.
Zurück zum Zitat Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J. 2009;73:925–31.PubMedCrossRef Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J. 2009;73:925–31.PubMedCrossRef
20.
Zurück zum Zitat Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989;63:18J–24J.PubMedCrossRef Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989;63:18J–24J.PubMedCrossRef
21.
Zurück zum Zitat Chilian WM, Eastham CL, Marcus ML. Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol. 1986;251:H779–88.PubMed Chilian WM, Eastham CL, Marcus ML. Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol. 1986;251:H779–88.PubMed
22.
Zurück zum Zitat Komaru T, Lamping KG, Eastham CL, Dellsperger KC. Role of ATP-sensitive potassium channels in coronary microvascular autoregulatory responses. Circ Res. 1991;69:1146–51.PubMedCrossRef Komaru T, Lamping KG, Eastham CL, Dellsperger KC. Role of ATP-sensitive potassium channels in coronary microvascular autoregulatory responses. Circ Res. 1991;69:1146–51.PubMedCrossRef
23.
Zurück zum Zitat Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26:541–7.PubMedCrossRef Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26:541–7.PubMedCrossRef
24.
Zurück zum Zitat Nakae I, Quan L, Hashimoto K, et al. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther. 1994;8:137–45.PubMedCrossRef Nakae I, Quan L, Hashimoto K, et al. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther. 1994;8:137–45.PubMedCrossRef
25.
Zurück zum Zitat Okamura A, Rakugi H, Ohishi M, et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol. 2001;37:719–25.PubMedCrossRef Okamura A, Rakugi H, Ohishi M, et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol. 2001;37:719–25.PubMedCrossRef
26.
Zurück zum Zitat Haager PK, Klues HG, Schmidt M, vom Dahl J, Hanrath P. Effects of nitroglycerin and nicorandil on regional poststenotic quantitative coronary blood flow in coronary artery disease: a combined digital quantitative angiographic and intracoronary Doppler study. J CardiovascPharmacol. 1999;33:126–34. Haager PK, Klues HG, Schmidt M, vom Dahl J, Hanrath P. Effects of nitroglycerin and nicorandil on regional poststenotic quantitative coronary blood flow in coronary artery disease: a combined digital quantitative angiographic and intracoronary Doppler study. J CardiovascPharmacol. 1999;33:126–34.
27.
Zurück zum Zitat Sadamatsu K, Tashiro H, Yoshida K, et al. Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon. Am J Cardiovasc Drugs. 2010;10:203–8.PubMedCrossRef Sadamatsu K, Tashiro H, Yoshida K, et al. Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon. Am J Cardiovasc Drugs. 2010;10:203–8.PubMedCrossRef
28.
Zurück zum Zitat Hayashi T, Ichikawa M, Iwata A, et al. Intracoronary nicorandil relieves multiple coronary vasospasm with hemodynamic collapse. Circ J. 2008;72:327–30.PubMedCrossRef Hayashi T, Ichikawa M, Iwata A, et al. Intracoronary nicorandil relieves multiple coronary vasospasm with hemodynamic collapse. Circ J. 2008;72:327–30.PubMedCrossRef
29.
Zurück zum Zitat Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006;113:2054–61.PubMedCrossRef Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006;113:2054–61.PubMedCrossRef
30.
Zurück zum Zitat Nakatani D, Sato H, Sakata Y, et al. Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocardial infarction. Am J Cardiol. 2007;100:1212–7.PubMedCrossRef Nakatani D, Sato H, Sakata Y, et al. Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocardial infarction. Am J Cardiol. 2007;100:1212–7.PubMedCrossRef
31.
Zurück zum Zitat Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557–67.PubMedCrossRef Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557–67.PubMedCrossRef
32.
Zurück zum Zitat Nestler DM, Noheria A, Haro LH, et al. Sustaining improvement in door-to-balloon time over 4 years. The Mayo Clinic ST-elevation myocardial infarction protocol. Circ Cardiovasc Qual Outcomes. 2009;2:508–13.PubMedCrossRef Nestler DM, Noheria A, Haro LH, et al. Sustaining improvement in door-to-balloon time over 4 years. The Mayo Clinic ST-elevation myocardial infarction protocol. Circ Cardiovasc Qual Outcomes. 2009;2:508–13.PubMedCrossRef
33.
Zurück zum Zitat Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial. J Am CollCardiol. 2010;56:463–9.CrossRef Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial. J Am CollCardiol. 2010;56:463–9.CrossRef
34.
Zurück zum Zitat Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997;30:1193–9.PubMedCrossRef Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997;30:1193–9.PubMedCrossRef
35.
Zurück zum Zitat Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:671–6.PubMedCrossRef Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:671–6.PubMedCrossRef
36.
Zurück zum Zitat Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358–61.PubMedCrossRef Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358–61.PubMedCrossRef
37.
Zurück zum Zitat Henry PJ, Horowitz JD, Louis WJ. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol. 1990;15:365–70.PubMedCrossRef Henry PJ, Horowitz JD, Louis WJ. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol. 1990;15:365–70.PubMedCrossRef
Metadaten
Titel
Beneficial Effects of Intracoronary Nicorandil on Microvascular Dysfunction After Primary Percutaneous Coronary Intervention: Demonstration of Its Superiority to Nitroglycerin in a Cross-Over Study
verfasst von
Noritoshi Ito
Shinsuke Nanto
Yasuji Doi
Yuma Kurozumi
Tomoaki Natsukawa
Hiroyuki Shibata
Masaya Morita
Atsushi Kawata
Ayumu Tsuruoka
Hirotaka Sawano
Ken-ichiro Okada
Yasuhiko Sakata
Tatsuro Kai
Toru Hayashi
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2013
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-013-6456-y

Weitere Artikel der Ausgabe 4/2013

Cardiovascular Drugs and Therapy 4/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.